CSF hypocretin-1 assessment in sleep and neurological disorders.
about
The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progressValidation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy.Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.Etiopathogenesis and neurobiology of narcolepsy: a review.Narcolepsy with long sleep time: a specific entity?Evidence for an association between migraine and the hypocretin receptor 1 geneFaster REM sleep EEG and worse restedness in older insomniacs with HLA DQB1*0602.Narcolepsy: a reviewCerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onsetPredictors of hypocretin (orexin) deficiency in narcolepsy without cataplexyCentral Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia.Cerebrospinal Fluid Orexin A Levels and Autonomic Function in Kleine-Levin Syndrome.Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation.Animal models of sleep disorders.Animal models of narcolepsy.Exploring the presence of narcolepsy in patients with schizophrenia.Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset.Sleepiness that cannot be overcome: narcolepsy and cataplexy.A unified survival theory of the functioning of the hypocretinergic system.Narcolepsy: a clinical review.Attention impairments and ADHD symptoms in adult narcoleptic patients with and without hypocretin deficiency.Orexin OX2 Receptor Antagonists as Sleep Aids.The ICSD-3 and DSM-5 Guidelines for Diagnosing Narcolepsy: Clinical Relevance and Practicality.Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia.[Brazilian guidelines for the treatment of narcolepsy].HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.Treatment of disorders of hypersomnolence.Sleep disorders of Whipple's disease of the brain.Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency.Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels.Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies.Neural Damage in Experimental Trypanosoma brucei gambiense Infection: Hypothalamic Peptidergic Sleep and Wake-Regulatory Neurons.Narcolepsy with Long Sleep Time: a Specific Entity?Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-UpPhysical Activity and Sleep/Wake Behavior, Anthropometric, and Metabolic Profile in Pediatric Narcolepsy Type 1
P2860
Q26751277-87C4612F-CA64-4B4A-BC1A-E570070604EDQ33635419-DE92E854-4581-4F80-8457-0B90AE78F2C5Q33950168-59A1AE14-F17B-40A9-A438-BC11D4864528Q34222793-B5A4FA9B-6108-4286-8FC3-FFF7CEAB9466Q34413665-6F6C72C4-7DF6-4BF7-B9C3-62F943B19451Q34611827-21224EAD-6D11-4447-95FC-2996479DFE38Q34770974-EDE04C16-93F5-4557-A564-6B8C941D88DBQ34810746-644DCA1B-FE3B-4D40-B1DA-19D9EC6BCBB7Q35212990-5978E124-F80A-4B8D-B008-493DD8E10E40Q36052900-517735F5-3D99-4F94-A7EE-905BA5D7D008Q36147074-4AB2914F-C8CB-4D84-82F0-6EB09E592844Q36411331-E5A999DD-2EB0-4575-AB70-BF51CDC20FE2Q36686510-8CADF04D-59E7-424A-8482-7212BA2B8CCBQ36708055-834EE66F-3770-4ADF-84D3-F5554F7F35F3Q36761993-16F7A34B-DE9A-49D9-94D9-798DE777E317Q36764549-B87E5F3F-F56E-4C46-B5E7-B001E2B142B0Q36955561-2DE29FC1-A3FE-4E2A-ADC4-0A6720131078Q37279136-CEA4E4A0-B3B2-4119-83EB-8E09EDCB5ACDQ37999433-DC8C8EA5-695E-466E-9711-E7269C812EECQ38103817-42E1F527-D641-4F6A-9BD7-FFD8B9CB1F04Q38211898-397E9C0F-FC58-4269-8896-026F860776AEQ38649226-70A7C646-053E-461B-AB1A-9665AE8D7FE1Q39026714-AEAB56A7-1296-4B5B-82DE-4CB76A036021Q39643178-77251CDA-AB3C-45AF-8F55-66A6CB1B3D6DQ40341088-62B88BE9-DBF9-4AC6-8806-555932E22613Q42859562-C1AA9A33-C3F9-401F-91BF-10F797448D9EQ42913561-F0A734BF-6748-4F5C-A336-01F462C845EEQ46026424-8A9E38DB-4839-40A9-B827-BBABB384D9F7Q48091835-5FF5F4D3-EEBD-4B7E-8504-4A4C4681A178Q48321095-362D37D0-37D9-4166-AE34-0F7853F01051Q48348538-3DBD5C0D-B027-47AB-BC6C-3DC5B245D5E5Q49829688-7EB10BE7-1A1A-4CA1-AA38-486107E7BF67Q51740583-C6F14452-4E2E-4081-B182-A95B6AF8D7E2Q55982726-767E16AC-94FE-497B-A9EA-FC5B022BC904Q58560764-DFF0211F-903A-404C-BEF2-D3594742562DQ58705806-D326C2B3-1D77-4B69-9056-74C66D6C8BBE
P2860
CSF hypocretin-1 assessment in sleep and neurological disorders.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CSF hypocretin-1 assessment in sleep and neurological disorders.
@ast
CSF hypocretin-1 assessment in sleep and neurological disorders.
@en
CSF hypocretin-1 assessment in sleep and neurological disorders.
@nl
type
label
CSF hypocretin-1 assessment in sleep and neurological disorders.
@ast
CSF hypocretin-1 assessment in sleep and neurological disorders.
@en
CSF hypocretin-1 assessment in sleep and neurological disorders.
@nl
prefLabel
CSF hypocretin-1 assessment in sleep and neurological disorders.
@ast
CSF hypocretin-1 assessment in sleep and neurological disorders.
@en
CSF hypocretin-1 assessment in sleep and neurological disorders.
@nl
P1433
P1476
CSF hypocretin-1 assessment in sleep and neurological disorders.
@en
P2093
Jamie M Zeitzer
P304
P356
10.1016/S1474-4422(08)70140-6
P577
2008-07-01T00:00:00Z